Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis

Stem Cell Research and Therapy

Volumn 5, Issue 2, 2014, Pages

  Lewis, Christina M ^a   Suzuki, Masatoshi ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SOMATOMEDIN; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL MIGRATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EXCITOTOXICITY; GLIA CELL; INTRAVENOUS ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL DIFFERENTIATION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFETY; STEM CELL EXPANSION; TREATMENT OUTCOME; ANIMAL; CYTOLOGY; HUMAN; MESENCHYMAL STROMA CELL; PROCEDURES;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84896762490     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt421     Document Type: Article

References (67)

1. Controversies and priorities in amyotrophic lateral sclerosis. MR Turner, O Hardiman, M Benatar, BR Brooks, A Chio, M de Carvalho, PG Ince, C Lin, RG Miller, H Mitsumoto, G Nicholson, J Ravits, PJ Shaw, M Swash, K Talbot, BJ Traynor, LH Van den Berg, JH Veldink, S Vucic, MC Kiernan, Lancet Neurol 2013 12 310 322
2. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. JA Morren, N Galvez-Jimenez, Expert Opin Investig Drugs 2012 21 297 320
3. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. DW Cleveland, JD Rothstein, Nat Rev Neurosci 2001 2 806 819
4. Riluzole for amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND). RG Miller, JD Mitchell, DH Moore, Cochrane Database Syst Rev 2012 3 CD001447
5. Riluzole blocks human muscle acetylcholine receptors. C Deflorio, E Palma, L Conti, C Roseti, A Manteca, E Giacomelli, M Catalano, C Limatola, M Inghilleri, F Grassi, J Physiol 2012 590 2519 2528
6. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. M Suzuki, CN Svendsen, Trends Neurosci 2008 31 192 198
7. Induced pluripotent stem cell lines derived from human somatic cells. J Yu, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, JL Frane, S Tian, J Nie, GA Jonsdottir, V Ruotti, R Stewart, II Slukvin, JA Thomson, Science 2007 318 1917 1920
8. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. BY Hu, JP Weick, J Yu, LX Ma, XQ Zhang, JA Thomson, SC Zhang, Proc Natl Acad Sci U S A 2010 107 4335 4340
9. Human mesenchymal stem cells: from basic biology to clinical applications. BM Abdallah, M Kassem, Gene Ther 2008 15 109 116
10. Mesenchymal stem cells: biology and potential clinical uses. RJ Deans, AB Moseley, Exp Hematol 2000 28 875 884
11. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. F Djouad, LM Charbonnier, C Bouffi, P Louis-Plence, C Bony, F Apparailly, C Cantos, C Jorgensen, D Noel, Stem Cells 2007 25 2025 2032
12. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. M Suzuki, J McHugh, C Tork, B Shelley, A Hayes, I Bellantuono, P Aebischer, CN Svendsen, Mol Ther 2008 16 2002 2010
13. Mesenchymal stem cell therapy for heart disease. M Gnecchi, P Danieli, E Cervio, Vascul Pharmacol 2012 57 48 55
14. Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease. P Kebriaei, S Robinson, Front Oncol 2011 1 16
15. Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases. I Kan, E Melamed, D Offen, Handb Exp Pharmacol 2007 180 219 242
16. Concise review: mesenchymal stem cells and translational medicine: emerging issues. G Ren, X Chen, F Dong, W Li, X Ren, Y Zhang, Y Shi, Stem Cells Transl Med 2012 1 51 58
17. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. DG Phinney, I Isakova, Curr Pharm Des 2005 11 1255 1265
18. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. H Ilieva, M Polymenidou, DW Cleveland, J Cell Biol 2009 187 761 772
19. Clinical translation of stem cells in neurodegenerative disorders. O Lindvall, RA Barker, O Brustle, O Isacson, CN Svendsen, Cell Stem Cell 2012 10 151 155
20. Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis. S Forostyak, P Jendelova, M Kapcalova, D Arboleda, E Sykova, Cytotherapy 2011 13 1036 1046
21. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. C Boucherie, S Schafer, P Lavand'homme, JM Maloteaux, E Hermans, J Neurosci Res 2009 87 2034 2046
22. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. M Dezawa, H Kanno, M Hoshino, H Cho, N Matsumoto, Y Itokazu, N Tajima, H Yamada, H Sawada, H Ishikawa, T Mimura, M Kitada, Y Suzuki, C Ide, J Clin Invest 2004 113 1701 1710
23. Adult rat mesenchymal stem cells differentiate into neuronal-like phenotype and express a variety of neuro-regulatory molecules in vitro. J Jiang, Z Lv, Y Gu, J Li, L Xu, W Xu, J Lu, J Xu, Neurosci Res 2010 66 46 52
24. Directed induction of functional motor neuron-like cells from genetically engineered human mesenchymal stem cells. HW Park, JS Cho, CK Park, SJ Jung, CH Park, SJ Lee, SB Oh, YS Park, MS Chang, PLoS One 2012 7 35244
25. Neural induction with neurogenin 1 enhances the therapeutic potential of mesenchymal stem cells in an amyotrophic lateral sclerosis mouse model. C Chan-Il, L Young-Don, K Heejaung, SH Kim, H Suh-Kim, SS Kim, Cell Transplant 2013 22 855 870
26. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. AM Haidet-Phillips, ME Hester, CJ Miranda, K Meyer, L Braun, A Frakes, S Song, S Likhite, MJ Murtha, KD Foust, M Rao, A Eagle, A Kammesheidt, A Christensen, JR Mendell, AH Burghes, BK Kaspar, Nat Biotechnol 2011 29 824 828
27. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. ST Papadeas, SE Kraig, C O'Banion, AC Lepore, NJ Maragakis, Proc Natl Acad Sci U S A 2011 108 17803 17808
28. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. SH Kang, Y Li, M Fukaya, I Lorenzini, DW Cleveland, LW Ostrow, JD Rothstein, DE Bergles, Nat Neurosci 2013 16 571 579
29. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. AM Clement, MD Nguyen, EA Roberts, ML Garcia, S Boillee, M Rule, AP McMahon, W Doucette, D Siwek, RJ Ferrante, RH Brown Jr, JP Julien, LS Goldstein, DW Cleveland, Science 2003 302 113 117
30. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. DR Beers, JS Henkel, Q Xiao, W Zhao, J Wang, AA Yen, L Siklos, SR McKercher, SH Appel, Proc Natl Acad Sci U S A 2006 103 16021 16026
31. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. AC Lepore, B Rauck, C Dejea, AC Pardo, MS Rao, JD Rothstein, NJ Maragakis, Nat Neurosci 2008 11 1294 1301
32. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. JC Dodge, CM Treleaven, JA Fidler, M Hester, A Haidet, C Handy, M Rao, A Eagle, JC Matthews, TV Taksir, SH Cheng, LS Shihabuddin, BK Kaspar, Mol Ther 2010 18 2075 2084
33. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. G Acsadi, RA Anguelov, H Yang, G Toth, R Thomas, A Jani, Y Wang, E Ianakova, S Mohammad, RA Lewis, ME Shy, Hum Gene Ther 2002 13 1047 1059
34. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. S Pun, AF Santos, S Saxena, L Xu, P Caroni, Nat Neurosci 2006 9 408 419
35. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. D Zisa, A Shabbir, G Suzuki, T Lee, Biochem Biophys Res Commun 2009 390 834 838
36. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. JF Ji, BP He, ST Dheen, SS Tay, Stem Cells 2004 22 415 427
37. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. SJ Greco, P Rameshwar, Ther Deliv 2012 3 997 1004
38. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Chen, Y Li, M Katakowski, X Chen, L Wang, D Lu, M Lu, SC Gautam, M Chopp, J Neurosci Res 2003 73 778 786
39. Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. M Gutierrez-Fernandez, B Fuentes, B Rodriguez-Frutos, J Ramos-Cejudo, MT Vallejo-Cremades, E Diez-Tejedor, J Cell Mol Med 2012 16 2280 2290
40. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. P Dharmasaroja, J Clin Neurosci 2009 16 12 20
41. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. I Kassis, A Vaknin-Dembinsky, D Karussis, Curr Stem Cell Res Ther 2011 6 63 68
42. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. D Krakora, P Mulcrone, M Meyer, C Lewis, K Bernau, G Gowing, C Zimprich, P Aebischer, CN Svendsen, M Suzuki, Mol Ther 2013 21 1602 1610
43. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. T Philips, W Robberecht, Lancet Neurol 2011 10 253 263
44. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. ED Hall, JA Oostveen, ME Gurney, Glia 1998 23 249 256
45. Immunosuppressive properties of mesenchymal stem cells: advances and applications. MP De Miguel, S Fuentes-Julian, A Blazquez-Martinez, CY Pascual, MA Aller, J Arias, F Arnalich-Montiel, Curr Mol Med 2012 12 574 591
46. Mesenchymal stem cell-based therapy. V Mundra, IC Gerling, RI Mahato, Mol Pharm 2013 10 77 89
47. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. I Kassis, N Grigoriadis, B Gowda-Kurkalli, R Mizrachi-Kol, T Ben-Hur, S Slavin, O Abramsky, D Karussis, Arch Neurol 2008 65 753 761
48. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. A Vercelli, OM Mereuta, D Garbossa, G Muraca, K Mareschi, D Rustichelli, I Ferrero, L Mazzini, E Madon, F Fagioli, Neurobiol Dis 2008 31 395 405
49. Human marrow stromal cells reduce microglial activation to protect motor neurons in a transgenic mouse model of amyotrophic lateral sclerosis. C Zhou, C Zhang, R Zhao, S Chi, P Ge, C Zhang, J Neuroinflammation 2013 10 52
50. Transplantation of mesenchymal stem cells in ALS. L Mazzini, A Vercelli, I Ferrero, M Boido, R Cantello, F Fagioli, Prog Brain Res 2012 201 333 359
51. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. L Mazzini, K Mareschi, I Ferrero, M Miglioretti, A Stecco, S Servo, A Carriero, F Monaco, F Fagioli, Cytotherapy 2012 14 56 60
52. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. H Deda, MC Inci, AE Kurekci, A Sav, K Kayihan, E Ozgun, GE Ustunsoy, S Kocabay, Cytotherapy 2009 11 18 25
53. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. M Blanquer, JM Moraleda, F Iniesta, J Gomez-Espuch, J Meca-Lallana, R Villaverde, MA Perez-Espejo, FJ Ruiz-Lopez, JM Garcia Santos, P Bleda, V Izura, M Saez, P De Mingo, L Vivancos, R Carles, J Jimenez, J Hernandez, J Guardiola, ST Del Rio, C Antunez, P De la Rosa, MJ Majado, A Sanchez-Salinas, J Lopez, JF Martinez-Lage, S Martinez, Stem Cells 2012 30 1277 1285
54. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. H Kim, HY Kim, MR Choi, S Hwang, KH Nam, HC Kim, JS Han, KS Kim, HS Yoon, SH Kim, Neurosci Lett 2010 468 190 194
55. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. S Knippenberg, N Thau, R Dengler, T Brinker, S Petri, PLoS One 2012 7 36857
56. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. D Karussis, C Karageorgiou, A Vaknin-Dembinsky, B Gowda-Kurkalli, JM Gomori, I Kassis, JW Bulte, P Petrou, T Ben-Hur, O Abramsky, S Slavin, Arch Neurol 2010 67 1187 1194
57. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. S Prabhakar, N Marwaha, V Lal, RR Sharma, R Rajan, N Khandelwal, Neurol India 2012 60 465 469
58. Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis. W Baek, YS Kim, SH Koh, SW Lim, HY Kim, HJ Yi, H Kim, J Neurosurg Sci 2012 56 261 263
59. Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis. D Krakora, C Macrander, M Suzuki, Neurol Res Int 2012 2012 379657
60. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. CP Zhao, C Zhang, SN Zhou, YM Xie, YH Wang, H Huang, YC Shang, WY Li, C Zhou, MJ Yu, SW Feng, Cytotherapy 2007 9 414 426
61. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. A Uccelli, M Milanese, MC Principato, S Morando, T Bonifacino, L Vergani, D Giunti, A Voci, E Carminati, F Giribaldi, C Caponnetto, G Bonanno, Mol Med 2012 18 794 804
62. Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. S Marconi, M Bonaconsa, I Scambi, GM Squintani, W Rui, E Turano, D Ungaro, S D'Agostino, F Barbieri, S Angiari, A Farinazzo, G Constantin, U Del Carro, B Bonetti, R Mariotti, Neuroscience 2013 248C 333 343
63. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. L Xu, P Shen, T Hazel, K Johe, VE Koliatsos, Neurosci Lett 2011 494 222 226
64. The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. SH Koh, W Baik, MY Noh, GW Cho, HY Kim, KS Kim, SH Kim, Exp Neurol 2012 233 472 480
65. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. GW Cho, MY Noh, HY Kim, SH Koh, KS Kim, SH Kim, Stem Cells Dev 2010 19 1035 1042
66. Stem cell treatment in amyotrophic lateral sclerosis. L Mazzini, K Mareschi, I Ferrero, E Vassallo, G Oliveri, N Nasuelli, GD Oggioni, L Testa, F Fagioli, J Neurol Sci 2008 265 78 83
67. Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility. HR Martinez, JF Molina-Lopez, MT Gonzalez-Garza, JE Moreno-Cuevas, E Caro-Osorio, A Gil-Valadez, E Gutierrez-Jimenez, OE Zazueta-Fierro, JA Meza, P Couret-Alcaraz, M Hernandez-Torre, Cell Transplant 2012 21 1899 1907